-
Pluristem Therapeutics Inc Granted European Patent For Use Of Cells To Help Treat Damaged Bone Marrow – Courtesy (Biospace)
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced that it has been issued...
-
Orphan drug market to reach $176bn by 2020 – Courtesy ( PMLiVe)
pharmacistThe global orphan drug market is expected to account for 19% of all branded prescription drug sales by 2020,...
-
Stem Cells and the Lawsuit That May Shape Our Medical Future – Courtesy (Forbes)
Regenerative Sciences, a medical company that pioneered a procedure to treat orthopedic injuries using patients’ own stem cells, is...
-
The Nasty Patent Games Drug Companies Play To Stop You From Getting Cheaper Drugs – Courtesy (TechDirt)
The astoundingly wonderful radio program/podcast Radiolab just recently had an episode called“Worth” — which included a few different stories trying...
-
Patent office rejects J&J arm’s plea for HIV drug intermediate – Courtesy (Financial Express)
In a setback to US consumer health behemoth Johnson & Johnson, India’s patent office has rejected an application from...
-
Senator asks VA to yank patent on Gilead’s Sovaldi to crush its price – Courtesy (Fierce Pharma)
Gilead Sciences ($GILD) has been able to withstand scathing criticism at home over the prices of its hep C...
-
Priority setting for orphan drugs: An international comparison
1-s2-0-s0168851010002691-mainDownload
-
Comparing first level patent data with value-added patent information: A case study in the pharmaceutical field q
1-s2-0-s0172219008000823-mainDownload
